Skip to main content
. 2004 Aug;53(8):1123–1128. doi: 10.1136/gut.2003.032896

Table 3.

 Metabolite concentrations of 130 steady state patients receiving concomitant therapy

AZA monotherapy (n = 36) AZA+5-ASA (n = 62) AZA + steroids (n = 16) Triple therapy (n = 16)
Range of individual mean TGN concns 70–591 (median 194) 88–717 (median 227) 118–524 (median 235) 70–438 (median 208)
Range of individual mean MeMPN concns 117–14267 (median 1567) 30–8564 (median 993) 228–12517 (median 1317) 302–4850 (median 1021)
Dose (mg/kg) 0.4–2.5 (median 1.8) 0.4–2.8 (median 1.8) 1.0–2.7 (median 2.0) 0.6–2.6 (median 1.7)

5-ASA, 5-aminosalicylic acid; AZA, azathioprine; MeMPN, methylmercaptopurine nucleotide; TGN, thioguanine nucleotide.

There was no significant difference in AZA dosage, TGN concentrations, or MeMPN concentrations in the four patient groups (Kruskal-Wallis, p = 0.9).

Metabolite concentrations are measured in pmol/8×108 red blood cells.